- Touchlight has partnered with SVF Vaccines to advance a Hepatitis B/D vaccine into clinical development.
- The collaboration uses Touchlight’s dbDNA platform to support scalable DNA manufacturing for vaccine development.
Touchlight has entered into a strategic partnership with SVF Vaccines to support the development of a Hepatitis B and D vaccine, with the aim of progressing the program into clinical development. The collaboration combines Touchlight’s DNA manufacturing capabilities with SVF’s vaccine design.
The agreement focuses on the use of Touchlight’s proprietary doggybone DNA (dbDNA) platform, an enzymatic DNA technology designed for scalable production of genetic materials. The platform is intended to support vaccine development by enabling efficient manufacturing and potential dose reduction compared to traditional plasmid DNA approaches.
SVF’s vaccine targets key viral components associated with Hepatitis B and D infections, including the PreS1 region and the HDV large antigen. According to the companies, this approach is designed to stimulate both antibody and T-cell responses to address infection and eliminate infected cells.
The collaboration aims to advance the vaccine candidate toward clinical development, addressing diseases that affect a large global patient population. The partnership reflects ongoing interest in new approaches to vaccine development using advanced DNA technologies.
“This partnership with SVF Vaccines highlights the significant capabilities of our dbDNA platform in advancing innovative vaccines.”
Jill Makin, Chief Scientific Officer of Touchlight
